Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Feb;165(2):253-266.
doi: 10.1016/j.chest.2023.10.046. Epub 2023 Nov 3.

Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Susanne Hansen  1 , Marianne Baastrup Søndergaard  2 , Anna von Bülow  2 , Anne-Sofie Bjerrum  3 , Johannes Schmid  3 , Linda M Rasmussen  4 , Claus R Johnsen  4 , Truls Ingebrigtsen  5 , Kjell Erik Julius Håkansson  6 , Sofie Lock Johansson  7 , Maria Bisgaard  7 , Karin Dahl Assing  8 , Ole Hilberg  9 , Charlotte Ulrik  6 , Celeste Porsbjerg  10
Affiliations
Free article
Observational Study

Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies

Susanne Hansen et al. Chest. 2024 Feb.
Free article

Abstract

Background: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal.

Research question: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment?

Study design and methods: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined "clinical response" to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. "Clinical remission" was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV1 > 80%) and a six-question Asthma Control Questionnaire score ≤ 1.5 following 12 months of treatment.

Results: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy.

Interpretation: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

Keywords: biologics; epidemiology; remission; severe asthma.

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: S. H. reports speaker fees from AstraZeneca; M. B. S. reports speaker fees from GSK; A. v. B. reports consulting fees from Novartis, speaker fees from Novartis, GSK, and AstraZeneca, travel grants from AstraZeneca, and participation in advisory boards with AstraZeneca and Novartis; A.-S. B. reports lecture fees from AstraZeneca and GSK; L. M. R. has received lecture fees from AstraZeneca, GSK, and Teva, support for attending meetings and/or travel received from AstraZeneca and Chiesi, and participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, GSK, and Teva; K. E. J. H. reports grants from SanofiGenzyme and AstraZeneca, lecture fees from AstraZeneca, GSK, Chiesi, TEVA, and SanofiGenzyme; O. H. reports support attending meetings from Sanofi, and participation in advisory boards with GSK, MSD, Sanofi, AstraZeneca, TEVA, and ALK; C. U. reports grants from Sanofi, Boehringer Ingelheim, AstraZeneca, and Novartis, consulting fees from Chiesi, Orion Pharma, AstraZeneca, GSK, Teva, Menarini, and Takeda, lecture fees from Orion Pharma, AstraZeneca, and TEVA, and participation in advisory boards with Novartis, GSK, AstraZeneca, Pfizer, Sanofi, Chiesi, and Boehringer Ingelheim; C. P. reports grants from AstraZeneca, GSK, Novartis, Teva, Sanofi, Chiesi, and ALK, consulting fees from AstraZeneca, GSK, Novartis, TEVA, Sanofi, Chiesi, and ALK, lecture fees from AstraZeneca, GSK, Novartis, TEVA, Sanofi, Chiesi, and ALK, participation in advisory boards with AstraZeneca, Novartis, TEVA, Sanofi, and ALK. None declared (J. S., C. R. J., T. I., S. L. J., M. B., K. D. A.).

Similar articles

  • Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
    Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Perez-de-Llano L, et al. Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC. Am J Respir Crit Care Med. 2024. PMID: 38701495 Free PMC article.
  • Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort.
    Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J, Timmermann H, Schulz C, Schmidt O, Ehmann R, Hamelmann E, Idzko M, Taube C, Lommatzsch M, Buhl R, Korn S. Milger K, et al. J Allergy Clin Immunol Pract. 2023 Sep;11(9):2701-2712.e2. doi: 10.1016/j.jaip.2023.05.047. Epub 2023 Jun 8. J Allergy Clin Immunol Pract. 2023. PMID: 37301433
  • Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
    Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Menzies-Gow A, et al. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14. Adv Ther. 2022. PMID: 35287231 Free PMC article.
  • Biologics for severe asthma and beyond.
    Mümmler C, Milger K. Mümmler C, et al. Pharmacol Ther. 2023 Dec;252:108551. doi: 10.1016/j.pharmthera.2023.108551. Epub 2023 Oct 30. Pharmacol Ther. 2023. PMID: 37907197 Review.
  • Biologics for severe asthma-Which, when and why?
    Shah PA, Brightling C. Shah PA, et al. Respirology. 2023 Aug;28(8):709-721. doi: 10.1111/resp.14520. Epub 2023 May 24. Respirology. 2023. PMID: 37222237 Review.
See all similar articles

Cited by

  • Clinical Remission Predictors in Non-Colonized Bronchiectasis and Severe Asthma with Type 2-Targeted Biologic Therapy: A Retrospective Real-Life Pilot Study.
    Quaranta VN, Portacci A, Montagnolo F, Dragonieri S, Iorillo I, Lulaj E, Maselli L, Buonamico E, Carpagnano GE. Quaranta VN, et al. J Clin Med. 2024 Oct 22;13(21):6309. doi: 10.3390/jcm13216309. J Clin Med. 2024. PMID: 39518449 Free PMC article.
  • Clinical remission and control in severe asthma: agreements and disagreements.
    Bosi A, Lombardi C, Caruso C, Cottini M, Baglivo I, Colantuono S, Menzella F. Bosi A, et al. Drugs Context. 2024 Sep 23;13:2024-7-2. doi: 10.7573/dic.2024-7-2. eCollection 2024. Drugs Context. 2024. PMID: 39347105 Free PMC article. Review.
  • Epigenetic patient stratification via contrastive machine learning refines hallmark biomarkers in minoritized children with asthma.
    Gorla A, Witonsky J, Elhawary JR, Chen ZJ, Mefford J, Perez-Garcia J, Huntsman S, Hu D, Eng C, Woodruff PG, Sankararaman S, Ziv E, Flint J, Zaitlen N, Burchard E, Rahmani E. Gorla A, et al. Res Sq [Preprint]. 2024 Sep 13:rs.3.rs-5066762. doi: 10.21203/rs.3.rs-5066762/v1. Res Sq. 2024. PMID: 39315258 Free PMC article. Preprint.
  • Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
    Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Ławkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Porsbjerg CM, et al. Front Immunol. 2024 Apr 19;15:1361891. doi: 10.3389/fimmu.2024.1361891. eCollection 2024. Front Immunol. 2024. PMID: 38711495 Free PMC article.
  • Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
    Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Perez-de-Llano L, et al. Am J Respir Crit Care Med. 2024 Oct 1;210(7):869-880. doi: 10.1164/rccm.202311-2192OC. Am J Respir Crit Care Med. 2024. PMID: 38701495 Free PMC article.
See all "Cited by" articles

Publication types